|

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

RECRUITINGPhase 1Sponsored by Samsung Bioepis Co., Ltd.
Actively Recruiting
PhasePhase 1
SponsorSamsung Bioepis Co., Ltd.
Started2026-03-23
Est. completion2030-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07524348

Summary

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.

Exclusion Criteria:

* Have spinal cord compression or clinically active central nervous system metastases
* Have leptomeningeal disease
* Have thromboembolic or clinically significant bleeding events
* Have significant cardiovascular disease
* Have an active autoimmune disease

Conditions2

Advanced Solid TumorsCancer

Interventions1

E303

Locations1 site

Research Site
Fairfax, Virginia, 22031

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.